Anders Olsson

Karolinska Institutet — Sweden

Medicine · Health Sciences

73h-index31.8kcitations637works5.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lipoproteins and Cardiovascular Health(245), Diabetes, Cardiovascular Risks, and Lipoproteins(76), Health Systems, Economic Evaluations, Quality of Life(48), Cancer, Lipids, and Metabolism(48), Social and Educational Sciences(41)

Publications633 total

Evaluating Short Forward Error Correction Codes for Avoiding Detection in Airborne Networks
2025Open Access
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
Circulation·2025· 16 citedOpen Access
Empowering Regional Conservation: Genetic Diversity Assessments as a Tool for Eelgrass Management
Molecular Ecology·2025· 3 citedOpen Access
Management of Rectus Diastasis
2025
Reading for Nobel and the Idea of the Universal
2024Open Access
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
European Heart Journal - Cardiovascular Pharmacotherapy·2024· 16 citedOpen Access
Supplementary Figure Legends from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure Legends from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 2 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 5 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 3 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Data from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Data from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 1 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 4 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 5 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 3 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 4 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 2 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
Supplementary Figure 6 from Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
2023Open Access
page 1 of 32Next →

Frequent Co-authors

Terje R. Pedersen(19), Gregory G. Schwartz(14), John Kjekshus(11), Ole Færgeman(10), Ingar Holme(10), Kalevi Pyörälà(8), Michael Szarek(7), Hallvard Holdaas(5), Bengt Fellström(5), Alan G. Jardine(5), Carola Grönhagen‐Riska(5), Edward Cole(5), Bart Maes(5), Patrice M. Ambühl(5), Hans Wedel(5), Thomas J. Cook(5), John J.P. Kastelein(5), William J. Sasiela(5), Lars Wilhelmsen(4), Guðmundur Þorgeirsson(4)